RCS - Oxford BioDynamics - OBD partners with Regina Maria in Romania

Oxford BiodynamicsAnnouncement

12/02/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250212:nRSL7501Wa&default-theme=true

RNS Number : 7501W  Oxford BioDynamics PLC  12 February 2025

 

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics partners with Regina Maria to offer EpiSwitch clinical
tests in Romania

·    Regina Maria is Romania's largest private healthcare provider,
serving 5 million patients

·    OBD's EpiSwitch PSE and CiRT tests will be available to physicians
and patients in Romania as part of Regina Maria's oncology portfolio

Oxford, UK - 12 February 2024 - Oxford BioDynamics Plc (AIM: OBD, the
"Company"), a precision clinical diagnostics company bringing specific and
sensitive tests to the practice of medicine based on its EpiSwitch® 3D
genomics platform, and Regina Maria Private Health Network, the leading
medical services provider in Romania, have signed a distribution agreement to
give patients in Romania access to OBD's clinical EpiSwitch PSE (EpiSwitch
Prostate Screening) and EpiSwitch CiRT (Checkpoint inhibitor Response Test)
blood tests.

Regina Maria (http://www.reginamaria.ro/) is the largest private healthcare
provider in Romania, serving 5 million patients with an array of medical
services. It operates 8 hospitals (3 JCI-accredited), 60 own polyclinics with
over 400 partner clinics, 36 medical laboratories and over 100 blood
collection points, 30 imaging centres and over 720,000 patients covered health
insurance subscriptions.

Under this new agreement, Regina Maria has the right to market and offer OBD's
EpiSwitch PSE and CiRT clinical tests throughout Romania, leveraging their
established medical and insurance networks. Patients' blood samples will be
shipped for analysis to OBD's UKAS-accredited ISO-15189 clinical testing
laboratory in Oxford.

Corina Olareanu, Laboratory Director at Regina Maria, said: "We know that
early and accurate diagnosis and informed therapy selection can be the
difference between successful treatment and disease progression, which is why
we are dedicated to equipping doctors with the most advanced diagnostics
available. By offering the EpiSwitch PSE and CiRT blood tests in Romania, we
are expanding our portfolio of oncology tools that can provide powerful and
convenient diagnostic insights for our medical network. The partnership with
OBD shows our commitment to innovation and strengthens our position as the
leading provider of next-generation health services in Romania."

Iain Ross, Executive Chairman of OBD, said: "OBD welcomes Regina Maria as our
partner, as we continue to work diligently to broaden availability of our
diagnostic tests through partnerships. Through this collaboration, we aim to
ensure that patients in Romania-the first in the EU to adopt EpiSwitch
clinical tests into private healthcare-have convenient, widespread access to
EpiSwitch PSE as a highly accurate test for prostate cancer risk, and
EpiSwitch CiRT for those considering or on cancer immunotherapy."

EpiSwitch PSE (https://94percent.com/) is OBD's validated, rapid, highly
accurate blood test for prostate cancer (accuracy 94%, specificity 97%,
sensitivity 86%)(1), significantly boosting the accuracy of PSA alone. With
the PSE, more than 9 out of every 10 men who receive a positive "high
likelihood" PSE will go on to have a confirmatory biopsy(1). This level of
performance can reduce the number of men who do not have prostate cancer being
referred for unnecessary MRI scans and invasive biopsies(2). These clinical
results are supported by an accumulation of real-world evidence related to the
clinical utility.

OBD's EpiSwitch CiRT (https://mycirt.com/) is a smart blood test that
accurately identifies patients who may respond to a widely used class of
cancer therapies(2)-Immune Checkpoint Inhibitors (ICIs)-with a binary result
(responder vs. non-responder) to support treatment planning, making more
informed treatment decisions when no benefit or disease progression is
observed, or when adverse events occur. The test can also identify candidates
for ICI therapy where other options have been exhausted or other tests are
negative for use.

- Ends -

References

1: Pchejetski D., et al. Cancers
(2023). https://doi.org/10.3390/cancers15030821
(https://doi.org/10.3390/cancers15030821)

2: Hunter, E., et al. Cancers (2023). https://doi.org/10.3390/cancers15102696
(https://doi.org/10.3390/cancers15102696)

 

For more information:

 Oxford BioDynamics PLC                                               +44 (0)1865 518910

 Paul Stockdale, CFO

 Iain Ross, Executive Chairman

 Shore Capital - Nominated Adviser and Joint Broker                   +44 (0)20 7408 4090

Advisory: Stephane Auton / Lucy Bowden

 Broking: Fiona Conroy

+44 (0)203 973 3678
 OAK Securities - Joint Broker

 Jerry Keen / Henry Clarke / Damion Carruel

 WG Partners - Joint Broker                                           +44 (0)20 3705 9330

 David Wilson / Claes Spång / Satheesh Nadarajah / Erland Sternby

 Vigo Consulting  Media / Analyst enquiries for OBD                   +44 (0)20 7390 0230

Rozi Morris

                                                                    obd@vigoconsulting.com

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company,
advancing personalized healthcare by developing and commercializing precision
clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the EpiSwitch® PSE
(https://www.94percent.com/)  (EpiSwitch Prostate Screening
test) and EpiSwitch® CiRT (https://mycirt.com/index.html)  (Checkpoint
Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a
PSA test from 55% to 94% when testing the presence or absence of prostate
cancer. CiRT is a highly accurate (85%) predictive response test to
immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform,
EpiSwitch® which enables screening, evaluation, validation and monitoring of
biomarkers to diagnose patients or determine how individuals might respond to
a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader
range of indications, and new tests are being developed in the areas of
oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US
operations and clinical laboratory are in Maryland, USA, along with a
reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more
information, please visit the Company's website, www.oxfordbiodynamics.com
(http://www.oxfordbiodynamics.com) ,  X (@OxBioDynamics) or LinkedIn
(https://www.linkedin.com/company/oxford-biodynamics/posts/?feedView=all) .

 

About Regina Maria

The REGINA MARIA Healthcare Network is the leader in the quality of medical
services in Romania, being the only operator with three internationally
accredited hospitals.

At the same time, REGINA MARIA has also been an innovator in the corporate
medical services segment, introducing the concept of corporate subscriptions
in Romania nearly 25 years ago. More recently, the company has developed
specialised medical packages for SMEs and individuals, currently managing a
portfolio of over 720,000 subscriptions.

In the last 10 years, REGINA MARIA has invested nearly 200 million euros in
developing the Romanian medical system, by modernising or opening new
facilities, purchasing high-performance equipment, and training medical teams.

REGINA MARIA has its own presence in more than half of the country's counties
and provides nationwide coverage through over 400 of its own and partner
clinics.

The REGINA MARIA Healthcare Network brings together more than 7,500 employees
and collaborators, offering comprehensive hospitalisation and surgical
services, maternity, outpatient services, imaging, laboratory testing, and
stem cell storage to over 5 million patients.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAXAFFAPSEFA